middle.news
Chimeric Therapeutics Doses First Patients in Pivotal CAR-T Trial, Raises $5M
11:00am on Friday 31st of January, 2025 AEDT
•
Biotechnology
Read Story
Chimeric Therapeutics Doses First Patients in Pivotal CAR-T Trial, Raises $5M
11:00am on Friday 31st of January, 2025 AEDT
Key Points
First three patients dosed in Phase 1/2 CHM CDH17 CAR-T trial for GI cancers
Phase 1B ADVENT-AML trial expanded to include newly diagnosed AML patients
Complete response observed in AML patient treated with CHM CORE-NK + Vactosertib
Successful $5 million capital raise completed to support clinical programs
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE